Drug evaluation: AMG-531 for the treatment of thrombocytopenias

Lawrence Rice

Drug evaluation: AMG-531 for the treatment of thrombocytopenias

Research output: Contribution to journal › Review article › peer-review

Abstract

Amgen Inc is developing AMG-531, a peptibody that binds to the thrombopoietin receptor Mpl, for the potential treatment of immune thrombocytopenic purpura (ITP), chemotherapy-induced thrombocytopenia (CIT) and thrombocytopenia in myelodysplastic syndrome (MDS). Results of the US phase III trial in ITP are expected to be available in the second half of 2006, while a phase II trial in CIT is still underway. A Japanese phase II ITP study has been initiated, as has a phase II trial of MDS patients in the US and France.

Original language	English (US)
Pages (from-to)	834-841
Number of pages	8
Journal	Current Opinion in Investigational Drugs
Volume	7
Issue number	9
State	Published - Sep 2006

ASJC Scopus subject areas

Pharmacology
Drug Discovery

Divisions

Benign Hematology

Cite this

@article{2857373883264119a6d503c091e45984,

title = "Drug evaluation: AMG-531 for the treatment of thrombocytopenias",

abstract = "Amgen Inc is developing AMG-531, a peptibody that binds to the thrombopoietin receptor Mpl, for the potential treatment of immune thrombocytopenic purpura (ITP), chemotherapy-induced thrombocytopenia (CIT) and thrombocytopenia in myelodysplastic syndrome (MDS). Results of the US phase III trial in ITP are expected to be available in the second half of 2006, while a phase II trial in CIT is still underway. A Japanese phase II ITP study has been initiated, as has a phase II trial of MDS patients in the US and France.",

author = "Lawrence Rice",

year = "2006",

month = sep,

language = "English (US)",

volume = "7",

pages = "834--841",

journal = "Current Opinion in Investigational Drugs",

issn = "1472-4472",

publisher = "Thomson Scientific Ltd.",

number = "9",

}

TY - JOUR

T1 - Drug evaluation

T2 - AMG-531 for the treatment of thrombocytopenias

AU - Rice, Lawrence

PY - 2006/9

Y1 - 2006/9

N2 - Amgen Inc is developing AMG-531, a peptibody that binds to the thrombopoietin receptor Mpl, for the potential treatment of immune thrombocytopenic purpura (ITP), chemotherapy-induced thrombocytopenia (CIT) and thrombocytopenia in myelodysplastic syndrome (MDS). Results of the US phase III trial in ITP are expected to be available in the second half of 2006, while a phase II trial in CIT is still underway. A Japanese phase II ITP study has been initiated, as has a phase II trial of MDS patients in the US and France.

AB - Amgen Inc is developing AMG-531, a peptibody that binds to the thrombopoietin receptor Mpl, for the potential treatment of immune thrombocytopenic purpura (ITP), chemotherapy-induced thrombocytopenia (CIT) and thrombocytopenia in myelodysplastic syndrome (MDS). Results of the US phase III trial in ITP are expected to be available in the second half of 2006, while a phase II trial in CIT is still underway. A Japanese phase II ITP study has been initiated, as has a phase II trial of MDS patients in the US and France.

UR - https://www.scopus.com/pages/publications/33748674848

UR - https://www.scopus.com/inward/citedby.url?scp=33748674848&partnerID=8YFLogxK

M3 - Review article

C2 - 17002262

AN - SCOPUS:33748674848

SN - 1472-4472

VL - 7

SP - 834

EP - 841

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

IS - 9

ER -

Drug evaluation: AMG-531 for the treatment of thrombocytopenias

Abstract

ASJC Scopus subject areas

Divisions

Other files and links

Fingerprint

Cite this